drugset
drugset / Trial / NCT02246816

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

NCT02246816 ↗

Phase 3 Withdrawn Marathon Pharmaceuticals, LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

MP-101 will be evaluated in this study to see if it is safe and tolerable.

Timeline

Start
2015-02
Primary completion
2018-02
Completion
2018-02

Outcome

Outcome not reported

Stopped: “Transfer of IND to different marketing authorization representative.”

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2979165 Unknown 0.6 ml —

Indications

short bowel syndrome